NCT05671601 is a clinical trial of Automatic picture recognition in Reproductive Medicine, sponsored by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School.

What drugs are being tested in NCT05671601?

Interventions in NCT05671601: Automatic picture recognition, Manual Assessment Group.

What condition does NCT05671601 study?

NCT05671601 studies Reproductive Medicine.

Is NCT05671601 still recruiting?

NCT05671601 is currently status unknown. Last updated 4 January 2023.

Last reviewed 2023-01-04 · How we verify

NCT05671601

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Application of Deep Learning to Jointly Assess Embryo Development to Improve Pregnancy Outcome of Embryo Transfer

Status unknown Last updated 4 January 2023

What this trial tests

trial testing Automatic picture recognition in Reproductive Medicine in 100 participants. Status unknown.

Timeline

30 December 2022

Primary endpoint
15 December 2023

15 June 2024

Quick facts

Lead sponsor	The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	30 December 2022
Primary completion	15 December 2023
Estimated completion	15 June 2024

Drugs / interventions tested

Automatic picture recognition
Manual Assessment Group

Conditions studied

Reproductive Medicine — all drugs for Reproductive Medicine →

Sponsor

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Who can join

Adults 20 to 40, female only, with Reproductive Medicine. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Aim of this research is to apply the deep learning automation based on Time-lapse imaging to jointly assess embryo development，so that it can ensure the consistency of embryo evaluation and improve the accuracy of evaluation.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School trials

Trials by the same sponsor.

NCT06966765 — Accelerated vs Standard Approach to Continuous Veno-venous Hemodiafiltration Post-hemoperfusion (ASAP) in Severe Acute D · Phase 3 · not yet recruiting
NCT07403071 — Validating Fish Oil's Role in Alleviating Bortezomib-Induced Neuropathy: A Multi-Method Study Integrating Big Data, Expe · not yet recruiting
NCT07532538 — A Machine Learning-Based Risk Prediction Model for Head and Neck Cancerous Lesions · not yet recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07399574 — Diagnostic Accuracy of A Diquat Quantitative Detection Kit and A Portable Mass Spectrometry System for Quantifying Diqua · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05671601 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Last refreshed: 4 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05671601.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing